Amylyx Pharmaceuticals, Inc.

NasdaqGS:AMLX Stok Raporu

Piyasa değeri: US$423.5m

Amylyx Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Amylyx Pharmaceuticals CEO'su Josh Cohen, Jan2013 tarihinde atandı, in görev süresi 11.83 yıldır. in toplam yıllık tazminatı $ 7.42M olup, şirket hissesi ve opsiyonları dahil olmak üzere 8.4% maaş ve 91.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 4.26% ine doğrudan sahiptir ve bu hisseler $ 18.03M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.9 yıl ve 3.8 yıldır.

Anahtar bilgiler

Josh Cohen

İcra Kurulu Başkanı

US$7.4m

Toplam tazminat

CEO maaş yüzdesi8.4%
CEO görev süresi11.8yrs
CEO sahipliği4.3%
Yönetim ortalama görev süresi3.9yrs
Yönetim Kurulu ortalama görev süresi3.8yrs

Son yönetim güncellemeleri

Recent updates

There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise

Nov 04
There's No Escaping Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) Muted Revenues Despite A 81% Share Price Rise

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry

Sep 18
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Stock Catapults 37% Though Its Price And Business Still Lag The Industry

Amylyx Pharmaceuticals: Potential To Redeem Itself With Data Readouts And Possible GLP-1 Acquisition

Jun 25

Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop

Apr 25
Lacklustre Performance Is Driving Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 31% Price Drop

Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically

Mar 12
Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically

An ALS Drug Fails Again

Mar 09

Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications

Feb 23

Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues

Feb 23
Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues

Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper

Nov 10
Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Sep 24
Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year

May 16
This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Apr 20
Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business

Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates

Mar 16
Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates

Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans

Dec 19
Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans

Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share

Oct 07

Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis

Sep 30

Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing

Sep 08

Amylyx plunges 28% after FDA briefing documents on ALS drug

Sep 02

We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate

Aug 29
We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate

Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.01

Aug 11

Amylyx Pharmaceuticals says ALS treatment Albrioza now available in Canada

Jul 29

Amylyx partners with Sunnybrook Research to identify neurodegenerative disease candidates

Jul 18

Amylyx: Thoughts Ahead Of September 29 PDUFA In Amyotrophic Lateral Sclerosis

Jul 04

CEO Tazminat Analizi

Josh Cohen'un ücretlendirmesi Amylyx Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$166m

Mar 31 2024n/an/a

-US$71m

Dec 31 2023US$7mUS$621k

US$49m

Sep 30 2023n/an/a

US$2m

Jun 30 2023n/an/a

-US$73m

Mar 31 2023n/an/a

-US$149m

Dec 31 2022US$7mUS$539k

-US$198m

Sep 30 2022n/an/a

-US$184m

Jun 30 2022n/an/a

-US$153m

Mar 31 2022n/an/a

-US$121m

Dec 31 2021US$1mUS$418k

-US$88m

Sep 30 2021n/an/a

-US$68m

Dec 31 2020US$671kUS$370k

-US$42m

Tazminat ve Piyasa: Josh 'nin toplam tazminatı ($USD 7.42M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.36M ).

Tazminat ve Kazançlar: Josh şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Josh Cohen (32 yo)

11.8yrs

Görev süresi

US$7,418,169

Tazminat

Mr. Joshua B. Cohen also known as Josh, co-founded Amylyx Pharmaceuticals, Inc. in 2013 and has been its Co-Chief Executive Officer and Director since January 2014. Mr. Cohen served as Chairman of the Boar...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Joshua Cohen
Co-Founder11.8yrsUS$7.42m4.26%
$ 18.0m
Justin Klee
Co-Founder11.8yrsUS$7.42m4.11%
$ 17.4m
James Frates
Chief Financial Officer3.8yrsUS$3.51m0.14%
$ 601.7k
Gina Mazzariello
Chief Legal Officer & General Counsel2.8yrsUS$3.01m0.21%
$ 888.0k
Camille Bedrosian
Chief Medical Officerless than a yearUS$2.37m0.030%
$ 127.8k
Tom Holmes
Chief Technical Operations Officerno dataVeri yokVeri yok
Lindsey Allen
Head of Investor Relations & Communicationsno dataVeri yokVeri yok
Shauna Horvath
Head of Global Marketing3.9yrsVeri yokVeri yok
Linda Arsenault
Chief Human Resources Officerless than a yearVeri yokVeri yok
Chris Aiello
Head of Canada & GM3.6yrsVeri yokVeri yok
Keith White
Head of Global Market Access3.9yrsVeri yokVeri yok
Tammy Sarnelli
Global Head of Regulatory Affairs4.3yrsVeri yokVeri yok

3.9yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim: AMLX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.9 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Joshua Cohen
Co-Founder10.8yrsUS$7.42m4.26%
$ 18.0m
Justin Klee
Co-Founder10.8yrsUS$7.42m4.11%
$ 17.4m
Peter Finn
Company Secretary & Member of Scientific Advisory Boardno dataVeri yokVeri yok
Walter Gilbert
Special Advisor & Member of Advisory Board3.8yrsUS$51.24kVeri yok
George Milne
Independent Chairman of the Board9.8yrsUS$385.07k1.26%
$ 5.3m
Rudolph Tanzi
Chairman of The Scientific Advisory Boardno dataVeri yokVeri yok
Alan Walts
Board Observer & Advisor7.3yrsVeri yokVeri yok
Karen Firestone
Independent Director1.7yrsUS$681.15k0.081%
$ 342.1k
Daphne Quimi
Independent Director3.4yrsUS$348.59k0.0073%
$ 31.1k
Bernhardt G. Zeiher
Independent Directorless than a yearVeri yokVeri yok
Sasha Bakhru
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Paul Fonteyne
Independent Director3.7yrsUS$342.12k0.0058%
$ 24.6k

3.8yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AMLX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).